Last reviewed · How we verify
LT3001 Drug Product
At a glance
| Generic name | LT3001 Drug Product |
|---|---|
| Also known as | LT3001 injection |
| Sponsor | Lumosa Therapeutics Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects (PHASE1)
- A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS (PHASE2)
- A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects (PHASE2)
- A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LT3001 Drug Product CI brief — competitive landscape report
- LT3001 Drug Product updates RSS · CI watch RSS
- Lumosa Therapeutics Co., Ltd. portfolio CI